HPV Genotyping

HPV Genotyping is a molecular diagnostic test that detects the presence of human papillomavirus (HPV) DNA and identifies specific viral genotypes, differentiating high‑risk types (associated with cervical and other anogenital cancers) from low‑risk types. The test typically uses PCR-based methods performed in accredited laboratories to provide genotype-specific, lab-certified results based on a self-collected vaginal swab, clinician-collected cervical swab, or appropriate urine sample. This at-home service delivers discreet sample collection and timely reporting across Dubai and the UAE, supporting early detection and clinical risk stratification.

The test is recommended for individuals with abnormal cervical cytology, persistent genital symptoms, or those seeking more precise risk assessment after a positive HPV screening. Results help clinicians decide on follow-up actions such as enhanced surveillance, colposcopy, or treatment, and can inform vaccination or counselling decisions. Always review genotyping results with a healthcare professional for interpretation and next steps within the UAE healthcare system.

• HPV DNA (Presence/Absence)
• HPV 16 genotype
• HPV 18 genotype
• Other high‑risk HPV genotypes (31,33,35,39,45,51,52,56,58,59,68)
• Low‑risk HPV genotypes (6,11)

• Abnormal Pap smear or cervical cytology result
• Presence of genital warts, lesions, or persistent symptoms
• Routine screening for sexually active adults, especially ≥30 years
• Post-treatment monitoring to confirm HPV clearance or persistence
• Before clinical decisions on colposcopy, treatment, or vaccination strategy

• Precise identification of HPV genotypes and associated oncogenic risk
• Supports targeted clinical follow‑up and timely specialist referral
• Useful for monitoring treatment response and long‑term clearance
• Discreet at‑home collection with lab‑certified reporting in the UAE
• Rapid turnaround enabling prompt clinical decision-making

• Self‑collected vaginal swab (or clinician‑collected cervical swab on request)
• First‑void urine may be accepted for male or non‑invasive testing
• Avoid sexual intercourse, douching, or vaginal products 24–48 hours before sampling
• Do not collect during active menstruation; test available for adults (18+) across Dubai and the UAE